A Rice University laboratory that specializes in synthesizing reagents and intermediate molecules for the design and manufacture of drugs and other fine chemicals has delivered on a promise to generalize the synthesis of electrophilic (electron-poor) aminating agents.
Aminating agents are valuable building blocks that can incorporate nitrogen atoms into molecules in a single efficient step without the use of contaminating metals or catalysts.
In his lab, Rice synthetic organic chemist László Kürti showed a tray piled high with the new reactivity-modifying agent, a nitrogen umpolung reagent used to synthesize aminating agents. An umpolung reverses the polarity of nitrogen atoms, which allows them to react differently with other atoms.
Kürti expects the robust umpolung reagent will give chemists easy access to highly sought-after, electron-poor nitrogen atoms when condensed with virtually any electron-rich primary amine.
The process is the subject of a paper in the Journal of the American Chemical Society.
When the design of a new drug involves trial and error and each trial may take hundreds of chemical steps over days and weeks, any effort to simplify existing synthetic routes is worthwhile, Kürti said. “This novel approach represents an operationally simple, scalable and environmentally friendly alternative to transition metal-catalyzed, carbon-nitrogen cross-coupling methods that are currently used to access structurally diverse amines,” he said.
Amines are compounds derived from ammonia molecules that have one nitrogen and three hydrogen atoms. In primary amines, one hydrogen is replaced by a substituent, like an aryl or an alkyl group. Secondary amines have only one hydrogen directly attached to the nitrogen besides the two substituents.
Rice’s electrophilic aminating agents simplify the production of secondary amines from readily available and inexpensive precursors. The agents enable the rapid formation of carbon-nitrogen bonds that are at the heart of a wide range of chemical compounds, including 80 percent of drug candidates and many agrochemicals, Kürti said.
Aminating agents form new carbon-nitrogen bonds in an unusual way because their nitrogen atoms are electron-poor; that is, they carry a partial positive charge and are able to react readily with carbon nucleophiles that are electron-rich.
“Convenient preparation of bench-stable electrophilic nitrogen sources has been an unmet synthetic need,” Kürti said. “This is due to the lack of a general and practical polarity-reversal method that converts abundantly available nitrogen-nucleophilic primary aliphatic and aromatic amines to the corresponding nitrogen-electrophilic aminating agents.”
The team led by Rice postdoctoral researcher Padmanabha Kattamuri solved the problem with a synthetic approach that relies on an umpolung reagent, ketomalonate hydrate, that reverses the nitrogen atom’s normal polarity. The lab can synthesize hundreds of grams of the reagent in a large reactor over 2 1/2 days.
Using the reagent to make structurally diverse electrophilic aminating agents eliminates the need for transition metals, ligands or forcing conditions like high temperatures or pressures or strong oxidants used in current amine syntheses, Kürti said.
Kattamuri said the lab used the contents of an open container of the umpolung reagent for nearly two years without any drop in its ability to function, which proved its stability.
“The synthetic and mechanistic results presented here constitute a breakthrough in the field of carbon-nitrogen bond-formation and will be of considerable interest not only to synthetic and medicinal chemists but also to the theoretical, structural and organometallic communities,” Kürti said.
Co-authors are postdoctoral researcher Jun Yin and undergraduate Surached Siriwongsup of Rice; graduate student Doo-Hyun Kwon and Daniel Ess, an associate professor of chemistry and biochemistry, of Brigham Young University; Qun Li of Nanjing University, China; Guigen Li, the Paul Whitfield Horn Professor at Texas Tech University; Muhammed Yousufuddin, a lecturer of chemistry at the University of North Texas at Dallas; and Paul Richardson and Scott Sutton of Pfizer Worldwide Research and Development in San Diego.
The research was supported by Rice University, the National Institutes of Health, the National Science Foundation, the Robert A. Welch Foundation, Amgen and Biotage.
Employers answer the call at Mayor’s Challenge conference to help prevent suicide https://t.co/4SqzgOFWNj via #VAntagePoint
Dr. Hugo Bellen and his lab are looking into the fruit fly's genes to find the ones that cause neurodevelopment and neurodegenerative disorders. https://t.co/Q9iZDBraWs #research @BCMFomtheLabs
It was great to see some of the #ManyFacesOfUTHealth working together yesterday at the @UTHealthCIPC mass casualty simulation drill to improve their skill sets and elevate their training! https://t.co/8SD8ipgbUO #collaboration #healthcare
RT @UTCVSurgery: The @UTHealth @McGovernMed @UTCVSurgery #Vascular team at the @VascularSVS #VAM2018 interactive poster session https://t.c…
RT @UTHealthCareers: Come Join the #UTHealth Team!!!! We have openings for all positions. Click the link below and join our team!!!! https:…
VA program using telemedicine to improve care of critically ill patients in regional hospitals appeared to reduce transfers to ICUs at larger facilities without compromising patient survival, researchers said. https://t.co/3shlLvcRbn via @HealthLeaders
Today’s #VeteranOfTheDay is @USArmy Veteran Joe Lopez. https://t.co/XNJFhMYYlM
RT @RiceUNews: Thanks to @MarkBermanFox26 and all the other #Houston media for visiting campus Thursday when we introduced @RiceBaseball's…
How we’re leading the way in #thyroidcancer treatment: https://t.co/MgHQp9I0Dd #endcancer
RT @davidleebron: Here’s the sequel. Gorgeousness from the opposite perspective at the end of the day. https://t.co/TOID4qgnLF
University of Houston@UHouston
RT @UH_MVP: Come volunteer next Saturday, take some time out of your summer to give back to our Houston community! https://t.co/wIdQtK3LmX
Today @Ppisters, @svargheseCHRO and other MD Anderson senior leaders set the pace for the President’s Fitness Challenge Row, Ride, Run. Next week, all employees are invited to form teams and try to beat Dr. Pisters’ time. #endcancer https://t.co/kHPILjnwi2
RT @CaroMuriel3: “ I don’t know where I’m going from here, but I promise it won’t be boring” David Bowie💃🏻🏃🏽♀️ Running on one of the best…
@NASARocketMan Thanks for reaching out. Please send a DM so we can get more info & have management follow up ^SF
ICYMI: Phase II clinical trial offers hope for first new therapeutic option for small cell #lungcancer in more than three decades: https://t.co/kn0V96ak9v #lcsm #endcancer